Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)
-
Multicenter Study Clinical Trial
[Is high-dose epinephrine justified in cardiorespiratory arrest in children?].
To evaluate the impact on survival of intravenous or intraosseous high-dose epinephrine compared with standard doses in children with cardiorespiratory arrest. ⋯ Although the present study has considerable limitations, the results suggest that high doses of epinephrine do not improve survival in cardiorespiratory arrest in children.
-
Multicenter Study
[Prevalence of mechanical ventilation in pediatric intensive care units in Spain].
To study the prevalence and characteristics of mechanical ventilation in children admitted to Spanish pediatric intensive care units (PICU). ⋯ A high percentage of children admitted to the PICU requires mechanical ventilation. The most frequent indication is respiratory failure. The most frequently used modality in children aged less than 1 month is pressure SIMV. In children older than 1 month volume-cycled or pressure-limited ventilation and volume-cycled SMIV are used in similar proportions. The prevalence of prolonged mechanical ventilation and the incidence of ventilator-associated complications are very high.
-
Multicenter Study
[Acute renal failure in critically-ill children. A preliminary study].
To analyze the characteristics of acute renal failure (ARF) in critically-ill children and develop a protocol for a multicenter study. ⋯ The incidence of ARF in critically-ill children is low but remains a cause of high mortality and prolonged stay in the PICU. Mortality was caused not by renal failure but by multiple organ failure.
-
Multicenter Study Clinical Trial
[Short course treatment for visceral leishmaniasis with liposomal amphotericin B in immunocompetent patients].
Visceral leishmaniasis is endemic in southern Europe. Traditional treatment consists of pentavalent antimonial compounds. However, treatment failures, the treatment's long duration, and toxicity have led to the introduction of new therapies, such as liposomal amphotericin B (LAB). In this study we evaluate the safety and efficacy of LAB at a maximum dose of 4 mg/kg/day on days 1, 2, 3, 4, 5, and 10. ⋯ A total dosage of 24 mg/kg of liposomal amphotericin B administered in 6 doses within 10 days is safe and effective for the treatment of visceral leishmaniasis and reduces the length of hospital stay.